Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
60°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
775.42
UNCHANGED
Streaming Delayed Price
Updated: 9:50 AM EDT, Jun 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Is the Vanguard S&P 500 Index Fund ETF a Buy Now?
Today 3:45 EDT
Via
The Motley Fool
Topics
ETFs
Economy
Government
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
June 30, 2025
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.
Via
Investor's Business Daily
$1,000 Invested in VUG Could Turn Into $50,000
June 29, 2025
Via
The Motley Fool
Topics
ETFs
Economy
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
June 29, 2025
Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value
Via
MarketBeat
Topics
Artificial Intelligence
Economy
This Dirt Cheap Healthcare Stock Could Be a Hidden Artificial Intelligence (AI) Opportunity (Hint: It's Not Eli Lilly)
June 29, 2025
Artificial intelligence (AI) has the potential to transform several different areas of the healthcare industry.
Via
The Motley Fool
Topics
Artificial Intelligence
Stocks
Which Stock Will Dominate the Weight Management Market Through 2030?
June 28, 2025
Via
The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
June 27, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
Spain Accuses Novo Nordisk Of Covert Advertising For Prescription Weight-Loss Drugs
June 27, 2025
MHRA launches genetic study into GLP-1 drug risks as Spain investigates Novo Nordisk for potential advertising violations.
Via
Benzinga
GLP-1 Showdown In India: Eli Lilly’s Mounjaro Pen Approved Just Days After Novo’s Wegovy Launch
June 26, 2025
Local drugmakers, including Sun Pharma, Biocon, Zydus, Cipla, and Dr. Reddy’s are racing to develop cheaper versions of semaglutide as its Indian patent nears expiry.
Via
Stocktwits
Topics
Intellectual Property
5 Biotech Stocks with Highly Anticipated Pending Results
June 26, 2025
Via
Stocktwits
Topics
Intellectual Property
Why This Weight Loss Drug Company's Stock Surged Today
June 26, 2025
Via
The Motley Fool
3 Growth Stocks I'm Loading Up On
June 26, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Government
5 Revealing Analyst Questions From Eli Lilly’s Q1 Earnings Call
June 26, 2025
Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging competitive pressures. Management credited the surge in sales to the...
Via
StockStory
Topics
Earnings
World Trade
Why Shares in Novo Nordisk Lost Weight Today
June 25, 2025
Via
The Motley Fool
US Adults Struggle With Long-Term Use Of Obesity Drugs Like Wegovy, Data Shows
June 25, 2025
GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only 8.1% stayed on therapy for three years.
Via
Benzinga
Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity
June 25, 2025
The company just initiated two Phase 3 studies of its weekly under-the-skin shot to stoke weight loss.
Via
Investor's Business Daily
What's Going On With Viking Therapeutics Stock On Wednesday?
June 25, 2025
Viking Therapeutics begins Phase 3 trials for VK2735, testing weekly injections in over 5,000 adults with obesity or type 2 diabetes over 78 weeks.
Via
Benzinga
Which S&P500 stocks are moving on Wednesday?
June 25, 2025
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.
Via
Chartmill
Tesla's Robotaxi Rollout
June 25, 2025
Via
The Motley Fool
Topics
Stocks
7 Space Stocks I'd Buy Without Hesitation
June 25, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Economy
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow
June 25, 2025
Via
The Motley Fool
Topics
Government
World Trade
Eli Lilly’s Newest Obesity Drug Candidate Stirs Wall Street Buzz, But Not Everyone’s Sold
June 25, 2025
Bimagrumab showed promising fat loss results in a mid-stage trial, but analysts raised concerns about safety and say more data is needed.
Via
Stocktwits
Novo's India Move Could Reshape The Weight-Loss Drug War With Eli Lilly
June 24, 2025
Novo Nordisk launches Wegovy in India, pricing it close to Eli Lilly's Mounjaro, while advancing global regulatory efforts for its GLP-1 portfolio.
Via
Benzinga
New AI Rollouts Signal Shift From Hype to Healthcare Reality
June 24, 2025
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:LLY),(NASDAQ:PLTR),(NYSE:PHG),(NASDAQ:WAY) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Hims & Hers CEO Hits Back At Novo Nordisk After Abrupt End Of Collaboration, Alleges Wegovy-Maker Is ‘Misleading The Public’
June 23, 2025
HIMS CEO said that the pharma company’s commercial team has been increasingly pressuring the company to control clinical standards and steer patients to Wegovy regardless of whether it is clinically...
Via
Stocktwits
Amgen Expands Development Plans For Highly Anticipated Obesity Drug
June 23, 2025
Amgen is expanding its plans for weight-loss drug, MariTide, with a trio of upcoming Phase 3 studies.
Via
Investor's Business Daily
Why Novo Nordisk Stock Is Sinking Today
June 23, 2025
Via
The Motley Fool
Topics
Stocks
Supply Chain
IWF Is a Great Choice for Most, But I Like VUG ETF Better
June 23, 2025
Via
The Motley Fool
Topics
ETFs
Novo Nordisk's Weight Loss Injection CagriSema Data Sparks Investor Concern
June 23, 2025
Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals.
Via
Benzinga
Eli Lilly's Investigational Oral Pill Shows Weight Loss Benefits With Lingering Side Effect Concerns
June 23, 2025
Eli Lilly's orforglipron reduced A1C and weight in type 2 diabetes, while weekly insulin efsitora matched daily insulin with fewer side effects.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.